Home › NDC Lookup › Ingredients › Omidenepag Isopropyl › 84826-0002-01
Omlonti omidenepag isopropyl .02 mg/mL Solution/ Drops, 1 bottle — NDC 84826-0002-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Omlonti omidenepag isopropyl .02 mg/mL Solution/ Drops, 1 bottle — NDC 84826-002-01 (Billing 84826-0002-01)

by Ocuvex Therapeutics, Inc. · 1 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC

This is a package of 1 bottle of Omlonti omidenepag isopropyl .02 mg/mL Solution/ Drops from Ocuvex Therapeutics, Inc., marketed since Sep 2022 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.

NDC 84826-0002-01
🏷️ FDA NDC (as labeled) 84826-002-01 billing pads the product segment with a zero
This package
Contains1 bottle Pack sizes2 compare ↓
Main listing for product 84826-002 · Also comes in: 3 bottles 84826-002-03
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 84826-002-01 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
84826 labeler · 002 product · 01 package
Package marketed since
Apr 28, 2025
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 8482600201 2
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 84826-002-01
Product NDC 84826-002
11-digit billing NDC 84826000201
NCPDP billing unit ML — per mL (volume)
RxCUI 2612702, 2612704
UNII G0G0H52U6K
Application # NDA215092
SPL Set ID 4258e437-7e92-4b09-baf1-01cb158cfc05
Established class (EPC) Prostaglandin E2 Receptor Agonist
Mechanism of action Prostaglandin E2 Receptor Agonists
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-09-23
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance OMIDENEPAG ISOPROPYL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 083873
GCN 41609
HICL code 048352
Ingredient (HICL) Omidenepag Isopropyl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6G
Therapeutic class — specific (HIC3) Miotics And Other Intraocular Pressure Reducers
AHFS code 52:40.28.00
AHFS class Prostaglandin Analogs
FDB label name OMLONTI 0.002% EYE DROP
FDB brand name Omlonti
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 083873
  • GCN: 41609
  • HICL (First Databank): 048352
  • AHFS class code: 52:40.28.00
  • RxCUI (RxNorm): 2612702
Why two NDCs? The FDA registers this code as 84826-002-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 84826-0002-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Prostaglandin E2 Receptor Agonist class.

Pharmacologic class Prostaglandin E2 Receptor Agonist
Drug family (ATC) Other antiglaucoma preparations
How it works Prostaglandin E2 Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name OMLONTI 0.002% EYE DROP Ingredient Omidenepag Isopropyl
📖 What it is MedlinePlus · NLM

Omidenepag isopropyl ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Omidenepag isopropyl is in a class of medications called prostaglandin agonists. It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It lowers high pressure inside your eye. Doctors prescribe it for open-angle glaucoma or ocular hypertension. Keeping eye pressure down helps protect your optic nerve and vision.
  • Put one drop in the affected eye(s) once a day in the evening. Shake the bottle gently first. If you wear contacts, take them out first and wait 15 minutes before putting them back...
  • Yes, but space them out. Wait at least 5 minutes between different eye drops. This helps each one do its job.
  • Eye redness is the most common one. Some people notice light sensitivity, blurry vision, dry eye, stinging, eye pain, or a headache. Let me or your eye doctor know if symptoms get...
📖 Read our full Omidenepag Isopropyl Ophthalmic guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 3 bottles
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
84826-0002-01 You're viewing this Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC 2025-04-28 — Active
84826-0002-03 84826-002-03 3 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC 2025-04-28 — Active

Pack size FAQ

What quantity is in this package?
This package contains 1 bottle — 1 bottle, plastic in 1 carton / 2.5 ml in 1 bottle, plastic.
How does this package differ from NDC 84826-0002-03?
Both are Omlonti omidenepag isopropyl .02 mg/mL Solution/ Drops — the drug itself is identical. This page's package is the 1 bottle one, while NDC 84826-0002-03 is the 3 bottles package.
What NDC number is used to bill for this package of Omlonti omidenepag isopropyl .02 mg/mL Solution/ Drops?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Omlonti .02 mg/mLthis 84826-0002-01 Ocuvex 1 bottle — — FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
First FDA approval
Sep 2022
📍
2026
Currently FDA-listed
4 years listed
🛡️
2039
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Jul 2039. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
📅 FDA approved Sep 22, 2022 RLD RS ⏳ ~12.8 yr to latest listed protection

Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.

Patents & exclusivity — FDA Orange Book
US 11666563 — method of use (U-3454)
US 12295946 — method of use (U-3454)
US 12290511 — method of use (U-3454)
US 11197849 — method of use (U-3454)
US 10702511 — method of use (U-3454)
US 10179127 — method of use (U-3454)
US 9415038 — method of use (U-3454)
US RE48183 — method of use (U-3454)
US 11793798 — method of use (U-3454)
US 10774072 — drug substance
US 8648097 — drug substance
US 8685986 — drug product
US 10765750 — drug product
Exclusivity NCE
2022 2024 2026 2028 2030 2032 2034 2036 2038
Today
LOE
Substance patent Formulation patent Method-of-use patent Exclusivity Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
Patent
Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
Substance patent
Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
Formulation (product) patent
Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
Method-of-use patent
A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
Skinny label
A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
Exclusivity
FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
Paragraph IV
A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
RLD / RS
Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
TE / AB rating
FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
LOE (loss of exclusivity)
The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.

Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.

Listed patents (13)
PatentTypeUse codeExpires
US 11666563 ↗ Method of use U-3454 Jul 16, 2039
US 12295946 ↗ Method of use U-3454 Jan 8, 2035
US 12290511 ↗ Method of use U-3454 Dec 27, 2038
US 11197849 ↗ Method of use U-3454 Jan 8, 2035
US 10702511 ↗ Method of use U-3454 Jan 8, 2035
US 10179127 ↗ Method of use U-3454 Jan 8, 2035
US 9415038 ↗ Method of use U-3454 Jan 8, 2035
US RE48183 ↗ Method of use U-3454 Jan 8, 2035
US 11793798 ↗ Method of use U-3454 Jan 8, 2035
US 10774072 ↗ Drug substance — Jun 10, 2035
US 8648097 ↗ Drug substance — Oct 13, 2029
US 8685986 ↗ Drug product — Oct 13, 2029
US 10765750 ↗ Drug product — Jan 8, 2035
FDA exclusivity
CodeWhat it grantsExpires
NCENew Chemical Entity (5-year)Sep 22, 2027
Common questions
Is there a generic version of OMLONTI 0.002% EYE DROP?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for OMLONTI 0.002% EYE DROP. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Jul 2039 — an estimate, not a guaranteed launch date.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Omidenepag Isopropyl Ophthalmic inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerOcuvex Therapeutics, Inc.
Application holderOCUVEX THERAPEUTICS INC
FDA applicationNDA215092 (NDA)
Labeler code84826
First marketedSep 2022
Product typeHuman Prescription Drug
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients 🧬 Pharmacokinetics 🔬 Clinical Studies 🧪 Nonclinical Toxicology 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Patient Package Insert 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 63 words ▾

1 INDICATIONS AND USAGE Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )

⏱️ Dosage and Administration 96 words ▾

2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. ( 2.1 )

2.1Recommended Dosage The recommended dosage is one drop in the affected eye(s) once daily in the evening.

2.2Administration Instructions Gently shake the bottle prior to administration. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. Contact lenses should be removed prior to the administration of Omlonti, and may be reinserted 15 minutes after administration [see Patient Counseling Information (17) ].

💊 Dosage Forms and Strengths 24 words ▾

3 DOSAGE FORMS AND STRENGTHS Omidenepag isopropyl ophthalmic solution: 0.002% (0.02 mg/mL) Ophthalmic solution containing 0.002% (0.02 mg/mL) of omidenepag isopropyl. ( 3 )

⛔ Contraindications 7 words ▾

4 CONTRAINDICATIONS None. None ( 4 )

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS Pigmentation ( 5.1 ) Eyelash changes ( 5.2 ) Ocular Inflammation ( 5.3 ) Macular Edema ( 5.4 )

5.1Pigmentation Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a prodrug of omidenepag, a relatively selective EP2 receptor agonist. Pigmentation is expected to increase as long as omidenepag isopropyl ophthalmic solution is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes.

After discontinuation of Omlonti, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes are likely to be reversible in most patients. Patients who receive prostaglandin analogs, including Omlonti, should be informed of the possibility of increased pigmentation, including permanent changes. The long-term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment.

While treatment with Omlonti (omidenepag isopropyl ophthalmic solution), 0.002% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly [see Patient Counseling Information (17) ] .

5.2Eyelash Changes Omlonti may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and the number of lashes or hairs. Eyelash changes are usually reversible upon discontinuation of treatment.

5.3Ocular Inflammation Ocular inflammation has been reported in patients taking Omlonti. Omlonti should be used with caution in patients with active ocular inflammation, including iritis/uveitis.

5.4Macular Edema Macular edema, including cystoid macular edema, has been reported during clinical trials in patients with pseudophakia receiving Omlonti. Omlonti should be used with caution in aphakic patients, in pseudophakic patients, or in patients with known risk factors for macular edema.

5.5Risk of Contamination and Potential Injury to the Eye Advise patients to avoid touching the tip of the bottle to the eye or any surface, as this may contaminate the solution. Advise patients to not touch the tip to their eye to avoid the potential for injury to the eye.

🤒 Adverse Reactions 214 words ▾

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Pigmentation [see Warnings and Precautions (5.1) ] Eyelash Changes [see Warnings and Precautions (5.2) ] Ocular Inflammation [see Warnings and Precautions (5.3) ] Macular Edema [see Warnings and Precautions (5.4) ] The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and visual impairment (1%).

( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ocuvex at 1-877-622-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to Omlonti in 600 patients for up to 3 months . The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and visual impairment (1%).

👥 Use in Specific Populations ~2 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary There are no available data on the use of Omlonti in pregnant women. In animal reproduction studies, subcutaneous administration of omidenepag isopropyl to pregnant rabbits throughout the period of organogenesis produced fetal skeletal anomalies at a dose of 24 times the clinical dose, based on estimated plasma C max . Omidenepag isopropyl was not teratogenic in rats when administered subcutaneously at 1 mg/kg/day, 2,452 times the clinical dose, based on estimated plasma C max (see Data ) .

Data Animal Data An embryofetal development study was conducted in pregnant rabbits administered omidenepag isopropyl once daily by subcutaneous injection at 0.008, 0.08, or 0.8 mg/kg/day from gestation Day 6 to 18, a period which covers implantation and the period of organogenesis in rabbits. Fetal skeletal anomalies (thoracic misaligned centrum and hemivertebra, fused sternebra, absent rib) were observed at 0.008 mg/kg/day (24 times the maximum recommended human ocular dose [MRHOD], based on estimated plasma C max ).

Additional fetal skeletal anomalies were observed at 0.08 mg/kg (absent thoracic arch, fused rib) and 0.8 mg/kg (misaligned and misshapen cervical vertebrae), corresponding to 256 times and 3,696 times the MRHOD based on estimated plasma C max , respectively. Increases in preimplantation loss and post-implantation loss were observed at 0.8 mg/kg/day. The rabbit maternal, No Observed Adverse Effect Level [NOAEL] was 0.8 mg/kg/day.

An embryofetal development study was conducted in pregnant rats administered omidenepag isopropyl once daily by subcutaneous injection at 0.01, 0.1, or 1 mg/kg/day from gestation Day 6 to 17, to target the period of organogenesis. Omidenepag isopropyl was not found to have any effect on embryo-fetal development in rats at up to 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C max ). The rat maternal NOAEL was 1 mg/kg/day.

In a pre/postnatal development study, treatment of pregnant rats with omidenepag isopropyl subcutaneously from gestation day 6 to lactation day 20 at 0.01, 0.1, or 1 mg/kg/day resulted in no adverse effects. The NOAEL for pre- and postnatal development was 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C max ).

8.2Lactation Risk Summary There are no data on the presence of Omlonti in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to omidenepag following topical ocular administration is low [see Clinical Pharmacology (12.3) ], and it is not known whether measurable levels of omidenepag would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Omlonti and any unknown potential adverse effects on the breast-fed child from Omlonti.

8.3Females and Males of Reproductive Potential Infertility There are no data on the effects of Omlonti on human fertility. No impairment of fertility has been reported in animals receiving omidenepag isopropyl subcutaneously at doses up to 2,452 times the clinical dose based on estimated plasma C max [see Nonclinical Toxicology (13.1) ] .

8.4Pediatric Use The safety and effectiveness of Omlonti have not been established in pediatric patients.

8.5Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary There are no available data on the use of Omlonti in pregnant women. In animal reproduction studies, subcutaneous administration of omidenepag isopropyl to pregnant rabbits throughout the period of organogenesis produced fetal skeletal anomalies at a dose of 24 times the clinical dose, based on estimated plasma C max . Omidenepag isopropyl was not teratogenic in rats when administered subcutaneously at 1 mg/kg/day, 2,452 times the clinical dose, based on estimated plasma C max (see Data ) .

Data Animal Data An embryofetal development study was conducted in pregnant rabbits administered omidenepag isopropyl once daily by subcutaneous injection at 0.008, 0.08, or 0.8 mg/kg/day from gestation Day 6 to 18, a period which covers implantation and the period of organogenesis in rabbits. Fetal skeletal anomalies (thoracic misaligned centrum and hemivertebra, fused sternebra, absent rib) were observed at 0.008 mg/kg/day (24 times the maximum recommended human ocular dose [MRHOD], based on estimated plasma C max ).

Additional fetal skeletal anomalies were observed at 0.08 mg/kg (absent thoracic arch, fused rib) and 0.8 mg/kg (misaligned and misshapen cervical vertebrae), corresponding to 256 times and 3,696 times the MRHOD based on estimated plasma C max , respectively. Increases in preimplantation loss and post-implantation loss were observed at 0.8 mg/kg/day. The rabbit maternal, No Observed Adverse Effect Level [NOAEL] was 0.8 mg/kg/day.

An embryofetal development study was conducted in pregnant rats administered omidenepag isopropyl once daily by subcutaneous injection at 0.01, 0.1, or 1 mg/kg/day from gestation Day 6 to 17, to target the period of organogenesis. Omidenepag isopropyl was not found to have any effect on embryo-fetal development in rats at up to 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C max ). The rat maternal NOAEL was 1 mg/kg/day.

In a pre/postnatal development study, treatment of pregnant rats with omidenepag isopropyl subcutaneously from gestation day 6 to lactation day 20 at 0.01, 0.1, or 1 mg/kg/day resulted in no adverse effects. The NOAEL for pre- and postnatal development was 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C max ).

🧒 Pediatric Use 16 words ▾

8.4Pediatric Use The safety and effectiveness of Omlonti have not been established in pediatric patients.

🧓 Geriatric Use 19 words ▾

8.5Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

🧬 Clinical Pharmacology ~1 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

12.3Pharmacokinetics Absorption Omlonti is absorbed through the cornea where prodrug omidenepag isopropyl is hydrolyzed to become biologically active metabolite, omidenepag. After once daily ocular administration of one drop of omidenepag isopropyl 0.0025% eye drops to both eyes in humans for 7 days, plasma concentrations of omidenepag reached C max at 10-15 minutes. Systemic exposure was similar between days 1 and 7, indicating no systemic accumulation.

Elimination Metabolism After topical ocular administration, omidenepag isopropyl is rapidly metabolized in the eye to omidenepag (active moiety) by carboxylesterase-1. The pharmacologically active form, omidenepag is further metabolized by liver through oxidation, N -dealkylation, glucuronidation, sulfate conjugation or taurine conjugation. Excretion In rats, 0.03% 14 C-Omlonti was instilled in both eyes as a single dose (5 mcL/eye, 3 mcg/animal).

By 168 hours after ocular instillation, 89% of the administered radioactive dose had been excreted. Specifically, 83% and 4% of the administered radioactive dose were excreted in the feces and urine, respectively, and radioactivity in expired air was below the lower limit of quantitation.

🧬 Mechanism of Action 56 words ▾

12.1Mechanism of Action Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

📦 How Supplied / Storage and Handling 93 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is supplied as a 2.5 mL sterile solution in 5 mL white low density polyethylene bottles with linear low density polyethylene dropper tips, high density polyethylene screw caps and tamper-evident low density polyethylene overcaps. Package of 1 bottle, NDC 84826-002-01 Multi-pack of 3 bottles, NDC 84826-002-03 Storage: Store unopened bottle (s) in the refrigerator at 2°C to 8°C (36°F to 46°F). Once a bottle is opened for use, it can be stored for up to 31 days at up to 30°C (86°F).

📦 Storage and Handling 36 words ▾

Storage: Store unopened bottle (s) in the refrigerator at 2°C to 8°C (36°F to 46°F). Once a bottle is opened for use, it can be stored for up to 31 days at up to 30°C (86°F).

📋 Description 153 words ▾

11 DESCRIPTION Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, contains the prodrug form of the active omidenepag, a relatively selective prostaglandin EP2 receptor agonist with ocular hypotensive activity. Omidenepag isopropyl is a white to light brown crystal or crystalline powder and practically insoluble in water. Omidenepag isopropyl's chemical name is Glycine, N-[6-[[[[4-(1H-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]-2-pyridinyl]-, 1-methylethyl ester and has the following structure: Structural Formula Formula of the free base: C 26 H 28 N 6 O 4 S.

Molecular weight: 520.61 Omlonti appears as a clear, colorless solution. It is supplied as a sterile, isotonic, buffered aqueous solution of omidenepag isopropyl with a target pH of 5.8 and an osmolality of approximately 285 mOsmol/kg. Each mL of Omlonti contains: Active: 0.02 mg of omidenepag isopropyl.

Preservative: 0.005% benzalkonium chloride. Inactive ingredients: glycerin, polyoxyl 35 castor oil, sodium citrate, citric acid monohydrate, edetate disodium, sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection. Chemical Structure

💬 Information for Patients ~1 min read ▾

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Instructions for Use). Potential for Pigmentation Patients should be advised about the potential for increased brown pigmentation of the iris, which may be permanent. Patients should also be informed about the possibility of eyelid skin darkening, which is usually reversible after discontinuation of Omlonti.

Potential for Eyelash Changes Patients should also be informed of the possibility of eyelash and vellus hair changes in the treated eye during treatment with Omlonti. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.

Handling the Container Advise patients to avoid touching the tip of the bottle to the eye or any surface, as this may contaminate the solution. Advise patients to not touch the tip to their eye to avoid the potential for injury to the eye. The product should be refrigerated before opening, and once it is opened, it can be stored at room temperature for up to 31 days . [see How Supplied/Storage and Handling (16) ] .

When to Seek Physician Advice Advise patients that if they develop a new ocular condition (e.g., trauma, infection, or inflammation), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of Omlonti. Use with Contact Lenses Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes after administration.

Use with Other Ophthalmic Drugs Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart [see Dosage and Administration (2) ] .

🧬 Pharmacokinetics 169 words ▾

12.3Pharmacokinetics Absorption Omlonti is absorbed through the cornea where prodrug omidenepag isopropyl is hydrolyzed to become biologically active metabolite, omidenepag. After once daily ocular administration of one drop of omidenepag isopropyl 0.0025% eye drops to both eyes in humans for 7 days, plasma concentrations of omidenepag reached C max at 10-15 minutes. Systemic exposure was similar between days 1 and 7, indicating no systemic accumulation.

Elimination Metabolism After topical ocular administration, omidenepag isopropyl is rapidly metabolized in the eye to omidenepag (active moiety) by carboxylesterase-1. The pharmacologically active form, omidenepag is further metabolized by liver through oxidation, N -dealkylation, glucuronidation, sulfate conjugation or taurine conjugation. Excretion In rats, 0.03% 14 C-Omlonti was instilled in both eyes as a single dose (5 mcL/eye, 3 mcg/animal).

By 168 hours after ocular instillation, 89% of the administered radioactive dose had been excreted. Specifically, 83% and 4% of the administered radioactive dose were excreted in the feces and urine, respectively, and radioactivity in expired air was below the lower limit of quantitation.

🔬 Clinical Studies 102 words ▾

14 CLINICAL STUDIES Omlonti was evaluated in three randomized and controlled clinical trials in subjects with open-angle glaucoma or ocular hypertension with average baseline IOP of 24-26 mm Hg. The double-masked treatment duration was 3 months in all 3 studies. The third study included a 9-month open-label treatment period following the 3-month double-masked treatment period.

In the three studies, IOP reductions were observed for all treatment arms. In the Omlonti arm, the reduction in IOP ranged from 5-7 mm Hg across all three studies. The corresponding reductions for the timolol and latanoprost arms were 5-7 mm Hg and 6-8 mm Hg, respectively.

🧪 Nonclinical Toxicology ~2 min read ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Lifetime rodent studies have not been performed to evaluate the carcinogenic potential of omidenepag isopropyl or omidenepag. In rats dosed by subcutaneous injection daily for 26 weeks, nephroblastoma and a spermatic cord tumor were found at 0.003 mg/kg/day (33 times the RHOD based on the estimated area under the curve [AUC]). Mammary adenocarcinoma and pituitary pars distalis adenomas were observed at 0.03 mg/kg/day (319 fold the RHOD based on the estimated AUC).

Mutagenesis Omidenepag was not mutagenic in the bacterial reverse mutation (Ames) test and the in vivo mouse micronucleus test. Omidenepag isopropyl was positive (mutagenic and clastogenic) without metabolic activation in the in vitro mouse lymphoma forward mutation assay. [see Clinical Pharmacology (12.3) ] . Impairment of Fertility In a rat fertility and early embryonic development study, daily subcutaneous doses of omidenepag isopropyl did not affect male or female fertility at doses up to 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C max ).

The rabbit embryofetal development study administered omidenepag isopropyl to pregnant rabbits beginning on gestation day 6, covering the period of implantation [see Use in Specific Populations (8.1) ] . Preimplantation losses were observed at 0.8 mg/kg/day (3,696 times the MRHOD based on estimated plasma C max ). The NOAEL for rabbit preimplantation loss was 0.08 mg/kg/day (256 times the MHROD based on estimated plasma C max ) [see Use in Specific Populations (8.1) ] .

13.2Animal Toxicology and/or Pharmacology Nasal cavity respiratory epithelium metaplasia was observed in cynomolgus monkeys receiving unilateral topical ocular instillations of omidenepag isopropyl at 0.003% (0.9 mcg/eye) [1.07 fold the MRHOD, based on ocular dose comparison]. In a 13-week monkey study, the 0.9 mcg/eye dose was associated with nasal cavity respiratory epithelial metaplasia, and increased nasal cavity goblet cell respiratory epithelium mucosa. In a 39-week monkey study, the 0.9 mcg/eye dose was associated with increased incidence and severity of nasal cavity respiratory epithelium metaplasia.

These findings were present in both the treated side and untreated contralateral side, and they were also observed in the vehicle group [see Adverse Reactions (6) ] .

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ~1 min read ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Lifetime rodent studies have not been performed to evaluate the carcinogenic potential of omidenepag isopropyl or omidenepag. In rats dosed by subcutaneous injection daily for 26 weeks, nephroblastoma and a spermatic cord tumor were found at 0.003 mg/kg/day (33 times the RHOD based on the estimated area under the curve [AUC]). Mammary adenocarcinoma and pituitary pars distalis adenomas were observed at 0.03 mg/kg/day (319 fold the RHOD based on the estimated AUC).

Mutagenesis Omidenepag was not mutagenic in the bacterial reverse mutation (Ames) test and the in vivo mouse micronucleus test. Omidenepag isopropyl was positive (mutagenic and clastogenic) without metabolic activation in the in vitro mouse lymphoma forward mutation assay. [see Clinical Pharmacology (12.3) ] . Impairment of Fertility In a rat fertility and early embryonic development study, daily subcutaneous doses of omidenepag isopropyl did not affect male or female fertility at doses up to 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C max ).

The rabbit embryofetal development study administered omidenepag isopropyl to pregnant rabbits beginning on gestation day 6, covering the period of implantation [see Use in Specific Populations (8.1) ] . Preimplantation losses were observed at 0.8 mg/kg/day (3,696 times the MRHOD based on estimated plasma C max ). The NOAEL for rabbit preimplantation loss was 0.08 mg/kg/day (256 times the MHROD based on estimated plasma C max ) [see Use in Specific Populations (8.1) ] .

📄 Patient Package Insert ~3 min read ▾

INSTRUCTIONS FOR USE OMLONTI ® [om lon’tee] (omidenepag isopropyl ophthalmic solution) 0.002% for topical ophthalmic use Read this Instructions for Use before you start using Omlonti and each time you get refills. There may be new and updated information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Important information you need to know before using Omlonti Omlonti is for use in the eye. Use Omlonti exactly as your healthcare provider tells you to use it. After you remove the Omlonti multi-dose bottle from the carton, make sure the tamper-evident overcap is not broken.

If the tamper-evident overcap is broken, Omlonti may not be safe for you to use. If you use Omlonti with other eye medicines, you should wait at least 5 minutes between using Omlonti and the other medicines. If you wear contact lenses, remove your contact lenses before using Omlonti.

You should wait 15 minutes after using Omlonti before placing your contact lenses back in your eye. Call your healthcare provider right away if you develop new eye problems including: an eye injury, eye infection, eye pain, light sensitivity, blurry vision, decreased vision, swelling and redness of the eye, problems with your eyelids, changes in the appearance of your eyes, headache, or eye surgery. If you develop blurred vision or light sensitivity after using Omlonti, do not drive or operate heavy machinery until the symptoms disappear.

Omlonti can cause color changes in your iris and eyelid and may change the length and color of your eyelashes. Using Omlonti Follow Step 1 to Step 11 each time you use Omlonti. Ask your healthcare provider for help if you do not understand how to use Omlonti.

Step 1 . Wash your hands thoroughly with soap and water. If you cannot wash your hands, you can clean your hands using hand sanitizer.

Step 2 . Turn the tamper-evident overcap to the left to open the multi-dose bottle. Step 3 .

Remove the tamper-evident overcap and throw it away. Step 4 . Gently shake the bottle.

Step 5 . Turn the inner screw cap to the left to remove it. Do not throw the inner screw cap away.

Step 6 . Pull down your lower eyelid with a clean finger. The medicine will go into the space between your lower eyelid and your eye.

Step 7 . Tilt your head back and look up. Step 8 .

Gently squeeze the multi-dose bottle to release 1 drop of the medicine in your eye. Do not let the tip of the multi-dose bottle touch your eye or any other surfaces. If a drop misses your eye, try again.

Step 9 . Blink a few times so that the medicine spreads across your eye. Step 10 .

After using Omlonti, gently close your eyelid and press the corner of your eye closest to your nose for 2 minutes. Step 11 . Repeat Step 6 to Step 10 for your other eye if you need to use drops in both eyes.

Storing Omlonti Store unopened Omlonti in the refrigerator between 36°F to 46°F (2°C to 8°C). After opening, store Omlonti up to 31 days at room temperature between 68°F to 86°F (20° to 30°C). Do not use Omlonti if the expiration date (EXP YYYY-MM) on the outer carton and multi-dose bottle have passed.

The expiration date is the last day of that month. After removing the tamper-evident overcap, keep the multi-dose bottle closed with the inner screw cap on to avoid contamination. Keep Omlonti and all medicines out of the reach of children.

Additional Information If you have questions about Omlonti, talk to your healthcare provider, or call Ocuvex Therapeutics Medical Information: 1-877-622-9326. Manufactured for: Ocuvex Therapeutics, Inc 1 Bridge Plaza, 2 nd Floor Fort Lee, NJ 07024 This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Approved: 09/2022 PIL-002-01 Rev: 10/2024 Image Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 Step 9 Step 10

📄 Package Label / Principal Display Panel 74 words ▾

PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Label NDC 84826-002-01 Ocuvex OMLONTI ® (omidenepag isopropyl ophthalmic solution) 0.002% FOR TOPICAL USE IN THE EYES STERILE RX ONLY 2.5 mL PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Label

PRINCIPAL DISPLAY PANEL - 2.5 mL Carton Label NDC 84826-002-01 Ocuvex OMLONTI ® (omidenepag isopropyl ophthalmic solution) 0.002% FOR TOPICAL USE IN THE EYES STERILE RX ONLY 2.5 mL PRINCIPAL DISPLAY PANEL - 2.5 mL Carton Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Omlonti (this brand).

Top reported reactions

Cataract18
Contraindicated Product Administered8
Cystoid Macular Oedema5
Intercepted Product Prescribing Error5
Anaphylactic Reaction4
Glaucoma4
Intraocular Pressure Increased4

Age at onset

Adult10
Elderly14

Reporter sex

61 reports
Male · 27%
Female · 73%

Serious outcomes

Disabling10
Hospitalization8
Reports over time (by year) — tap or hover for the count & year
2022 2023 2024 2026 21 1
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Ocuvex Therapeutics, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 3 bottles (84826-0002-03). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Ocuvex Therapeutics, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 84824-0007-01 · Zhejiang 84828-0569-00 · Invest →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.